ERBB2 and ovarian carcinoma: Cross-sectional cohort analysis of serum samples using the ExoCounter system showed a significant rise in receptor tyrosine-protein kinase erbB-2 (HER2)-positive exosomes in patients with breast or ovarian cancer compared to healthy individuals and patients without cancer [140].